Nektar Therapeutics (NKTR) Tops Q2 EPS by 1c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $59.21 +592,000.00%
Revenue Growth %: +141.7%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: +141.7%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.27), $0.01 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $20.5 million versus the consensus estimate of $21.79 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- H.C. Wainwright Reiterates Buy Rating on Anixa Biosciences (ANIX)
- MIND Technology (MIND) Misses Q1 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
